GSK Revives Shelved Drug Amid Political Tailwinds in Bid to Regain Pharma Standing

BTCC / BTCC Square / Global Cryptocurrency /

Author:

Release Time:

2025-09-25 00:21:02

BTCCSquare news:

GlaxoSmithKline (GSK) is leveraging U.S. political dynamics to reinvigorate its pharmaceutical pipeline, including the controversial reapproval of discontinued drug Leucovorin. The London-based firm, which once marketed the therapy as Wellcovorin, secured FDA clearance under pressure from the TRUMP administration to address autism—a move lacking robust clinical evidence but rich in political symbolism.

The timing of the decision, coinciding with a Trump-Kennedy autism event, underscores how policy shifts can reshape drug development priorities. GSK’s stock has outperformed rivals Pfizer and Merck over the past year, suggesting investor Optimism about its strategic pivot.

By:

Log in to Reply

Opendoor (OPEN) Stock Surges to $9 Amid Housing Market Optimism and Institutional Interest

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.